Lexicon Pharmaceuticals | LXRX - El Costo De Ventas





El Costo De Ventas Cambio Fecha
Abbott USD 4.92B 535M 2025-12
Acadia Pharmaceuticals USD 26.22M 4.58M 2025-12
Agios Pharmaceuticals USD 1.88M 199K 2025-12
Akebia Therapeutics USD 10.34M 441K 2025-12
Alnylam Pharmaceuticals USD 267.72M 67.57M 2025-12
AstraZeneca USD 3.27B 471M 2025-12
BioMarin Pharmaceutical USD 161.56M 16.62M 2025-12
Coherus Biosciences USD 4.04M 324K 2025-12
Eli Lilly USD 3.37B 363.7M 2025-12
Esperion Therapeutics USD 27.85M 13.43M 2025-12
Halozyme Therapeutics USD 102.15M 29.14M 2025-12
Illumina USD 400M 49M 2025-12
Insmed USD 46.16M 15.25M 2025-12
Ironwood Pharmaceuticals USD 29.83M 560K 2024-09
J&J USD 7.97B 689M 2025-12
Lexicon Pharmaceuticals USD 201K 191K 2025-12
MacroGenics USD 10.12M 34.18M 2025-12
MannKind USD 33.65M 13.44M 2025-12
Merck USD 3.32B 531M 2025-12
Moderna USD 452M 245M 2025-12
Novartis USD 3.54B 3M 2025-12
PTC Therapeutics USD 16.3M 7.02M 2025-12
Puma Biotechnology USD 29.1M 18.44M 2024-09
Sarepta Therapeutics USD 399.38M 247.93M 2025-12
Thermo Fisher Scientific USD 7.58B 674M 2025-12
Ultragenyx Pharmaceutical USD 29M 1.01M 2025-12
United Therapeutics USD 474.7M 373.8M 2025-12
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12